https://www.selleckchem.com/pr....oducts/wnt-c59-c59.h
006). Patients with FGFR3 mutation and low MATH value exhibit longer overall survival time than that of all BLCA patients (p = 0.044), which was replicated in another bladder cancer database composed of 109 BLCA patients. Measures of tumor heterogeneity may be useful biomarkers for identifying patients with bladder cancer. Low MATH value was an independent risk factor that predicted better prognosis for patients with FGFR3 mutation compared to all BLCA patients. Measures of tumor heterogeneity may be useful biomarkers for identifyin
Beğen
Yorum Yap
Paylaş
